Anthrax vaccine suspension for injection 0.5ml ampoules
Requires a prescription from a doctor or prescriber
Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*.
Safety information for pregnancy and breastfeeding
Pregnancy
available data on BioThrax (a licensed anthrax vaccine), administered to pregnant individuals are relevant to CYFENDUS because BioThrax and CYFENDUS contain the same active ingredient and are manufactured similarly.
In the observational study, there were more birth defects in infants born to individuals vaccinated with BioThrax in the first trimester compared to individuals vaccinated post-pregnancy or individuals never vaccinated with BioThrax.
In a developmental study with an embryo-fetal development toxicity phase, female rats were administered a full human dose (0.5 mL) of CYFENDUS twice prior to mating and once during gestation.
Always consult your doctor or midwife before taking any medicine during pregnancy or while breastfeeding. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Anthrax vaccine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Anthrax vaccine on the MHRA register
Anthrax vaccine (alum precipitated sterile filtrate) suspension for injection 0.5ml ampoules
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 15 · Randomised trials: 5 · 1962–2026
Showing the 50 most relevant studies, sorted by most relevant.
Alemu AT, Beyene BY, Molla Beza G, et al.
2026
- Anthrax
- Health Knowledge, Attitudes, Practice
- Health Policy
BackgroundAnthrax is one of the tropical diseases that are often overlooked... Anthrax's burden extends beyond its effects on health; it also has an economic cost. Implementing One Health policies requires knowledge, attitude, and practice (KAP) about anthrax prevention and control. However, there is no nationally aggregated evidence in Ethiopia. Therefore, this review was done to generate evidence and offer suggestions for incorporating KAP findings into One Health strategy to prevent and control anthrax in Ethiopia.MethodsThe protocol was registered in a PROSPERO with a reference CRD420251141478 and Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines were adhered. The electronic databases: Pub-Med, Scopus, Web of Science, CAB abstracts, AGRICOLA, and Google-Scholar were searched to retrieve the included studies using key search terms with database specific search strings. Studies that reported KAP outcomes in Ethiopian and were published only in English language irrespective of publication time were included in this review. The random-effects model was used to pool effect sizes using STATA 17 software. Subgroup and meta-regression analyses were performed to explore potential sources of heterogeneity, while sensitivity analysis was performed to assess the robustness of the pooled estimates. Forest plots were used to display the results.ResultsThis study included 17 articles with 8,369 participants that met the inclusion criteria. Our synthesis found that consuming raw meat, backyard slaughtering, improperly disposing of carcasses, and sharing a home with animals are common risk factors for anthrax infection in Ethiopia. The pooled knowledge, attitude, and practice levels of anthrax prevention and control were 51.25% (95% CI: 43.93, 58.58; I2 = 98.01%), 59.26% (95% CI: 50.43%, 68.08%; I2 = 98.33%), and 50.62% (95% CI: 42.95, 58.29; I2 = 97.93%), respectively.ConclusionsHalf of the communities in Ethiopia remain with suboptimal knowledge, attitudes, and practices for anthrax prevention and control. This could lead to ineffective outbreak management, delayed reporting, and continuous transmission of anthrax to humans and animals, particularly in endemic areas. As a result, from a One Health perspective, an integrated multisectoral intervention is urgently required to promote collaboration among the human, animal, and environmental health sectors.
Abstract licence: CC BY
Martin AF, Heinze N, Stein MV, et al.
2026
Post-exposure prophylaxis may be recommended during chemical, biological, radiological or nuclear (CBRN) emergencies and must often be initiated rapidly to be effective. Understanding factors that affect uptake (initiation) and subsequent adherence (completion) will help to minimise barriers and support adherence during emergencies. This systematic review synthesises evidence on factors associated with uptake of and adherence to prophylaxis following exposure to anthrax, radiation, smallpox, or viral pandemic diseases such as influenza or COVID-19. The review was pre-registered (https://osf.io/f5nmw). We searched Medline, Embase, APA PsycINFO, Web of Science, Scopus, the Cochrane Library, and subject specific databases, with no language or date restrictions. PRISMA and synthesis without meta-analysis (SWiM) guidelines were followed alongside NICE recommendations for risk of bias assessment. Data were extracted on factors associated with, and interventions targeting, uptake and adherence to prophylaxis across the four scenarios. Of 17,217 records screened, 21 studies were included. Uptake and adherence varied widely. Evidence on associated factors was inconsistent and generally of low certainty. Few scenario-specific differences were identified; variation was more strongly associated with population and contextual factors. Common barriers included concerns about side effects, low perceived risk, and lack of trust in information sources. Evidence on the effectiveness of interventions was limited to two studies, at high risk of bias. In conclusion, preparedness should prioritise addressing shared motivational and practical barriers across settings. There is a critical need to develop and evaluate interventions to support timely uptake and adherence to prophylaxis before emergencies occur.
Abstract licence: CC BY
Agbajelola V, Raghavan RK
2026
- Anthrax
- Population Surveillance
- Disease Outbreaks
BackgroundAnthrax remains a persistent public health, veterinary, and ecological challenge in Africa, sustained by fragmented surveillance systems characterized by underreporting, limited diagnostic capacity, and weak cross-sectoral coordination. The absence of integrated surveillance across human, livestock, wildlife, and environmental interfaces constrains accurate burden estimation and timely outbreak response.MethodsWe conducted a systematic review and meta-analysis following PRISMA guidelines to synthesize available evidence on anthrax epidemiology in Africa. Studies published between January 2000 and February 2025 were identified from PubMed and Web of Science. Observational studies reporting primary epidemiological data in humans, livestock, wildlife, or environmental samples were eligible. Quantitative synthesis was restricted to cross-sectional studies reporting extractable prevalence data. Pooled estimates were generated using a logit-transformed random-effects model (REML), with heterogeneity assessed using I 2 and τ2 statistics. Studies not meeting meta-analytic criteria were synthesized narratively within a One Health framework.ResultsTen cross-sectional studies comprising 19,955 samples and 2,079 confirmed anthrax cases were included in the meta-analysis. The crude aggregated prevalence was 9.88% (95% CI: 9.46%-10.30%). The pooled prevalence from the logit-transformed random-effects model was 20% (95% CI: 8%-44%). Substantial heterogeneity was observed (I 2 = 98.2%), indicating marked epidemiological variability across ecological settings, host populations, and surveillance systems. Narrative synthesis further highlighted wildlife outbreaks and environmental persistence of Bacillus anthracis, though such studies remain comparatively scarce.ConclusionThe available evidence on anthrax in Africa is limited, geographically uneven, and highly heterogeneous. The pooled estimate should therefore be interpreted as a summary measure of reported prevalence rather than a precise continental burden estimate. These findings underscore persistent transmission within fragmented surveillance systems and support strengthened One Health-based approaches integrating human, animal, wildlife, and environmental health sectors to improve surveillance, early detection, and coordinated response across Africa.
Abstract licence: CC BY
V DEMICHELI
Vaccine, 1998
G. Gorse, W. Keitel, H. Keyserling, et al.
Vaccine, 2006
N. Marano, B. Plikaytis, Stacey W. Martin, et al.
JAMA, 2008
Bojan Drobic, Gideon Akintunde, Julia Kim, et al.
Vaccine, 2026
- Anthrax
- Anthrax Vaccines
- Post-Exposure Prophylaxis
Peter C.B. Turnbull
Vaccine, 1991
P. Brachman, H. Gold, S. Plotkin, et al.
American journal of public health and the nation's health, 1962
B. Ivins, M. L. Pitt, P. Fellows, et al.
Vaccine, 1996
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
The anthrax vaccine induces antibodies raised against PA that may contribute to…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
Protein binding
Volume of distribution
Metabolism
Elimination
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566][L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world.[L47561]
[L47526]
BioThrax is also approved for the same condition but is also used for pre-exposure prophylaxis for people whose occupation or other activities place them at high risk of exposure.
[L47536]
The efficacy of CYFENDUS for post-exposure prophylaxis (PEP) is based solely on studies in animal models of inhalational anthrax.
[L47526]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 452 interactions
available data on BioThrax (a licensed anthrax vaccine), administered to pregnant individuals are relevant to CYFENDUS because BioThrax and CYFENDUS contain the same active ingredient and are manufactured similarly.
BioThrax does not contain CPG 7909 adjuvant. Data are available from a BioThrax observational study and pregnancy exposure registry.
[L47526]
In the observational study, there were more birth defects in infants born to individuals vaccinated with BioThrax in the first trimester compared to individuals vaccinated post-pregnancy or individuals never vaccinated with BioThrax. Data from the BioThrax pregnancy exposure registry do not establish the presence or absence of vaccine-associated risks in pregnancy.
[L47526]
In a developmental study with an embryo-fetal development toxicity phase, female rats were administered a full human dose (0.5 mL) of CYFENDUS twice prior to mating and once during gestation.
This study revealed no evidence of harm to the fetus, changes in reproductive performance, or adverse effects on post-natal development due to the vaccine.
[L47526]
The anthrax vaccine has not been evaluated for carcinogenicity, mutagenic potential, or male infertility in animals. Anthrax vaccine administered to female rats had no effect on fertility.
[L47526]
How the body processes this drug — absorption, distribution, metabolism, and elimination
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Anthrax vaccine
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72